The Ren Lab
To study tumor microenvironment and tumor immunology in cancer therapeutic resistance and metastatic relapse
Principal Investigator
Location
Connect
Topics
OUR RESEARCH FOCUS
The Ren group mainly focuses on elucidating how mesenchymal lineage cells (mesenchymal stem cells and fibroblasts) and immune-regulatory myeloid cells (neutrophils and macrophages) modulate the adaptive immune responses in cancer treatment resistance and metastatic relapse. These studies will fully take advantage of the unique research platform--patient-derived xenograft (PDX) tumors in humanized mouse models at The Jackson Laboratory, with the research goal to develop novel strategies targeting tumor microenvironment to improve the efficacies of conventional cancer therapies and new therapeutics such as immunotherapy.
-
Research HighlightSeptember 28, 2022Tipping the scale toward favorable outcomes in cancer and beyond
Jennifer Trowbridge and her team reveal the molecular signaling pathway most associated with clonal hematopoiesis and how blocking a specific cell-surface receptor in the pathway can tip the balance toward positive health outcomes. -
Research HighlightSeptember 08, 2022Measuring frailty in mice to examine aging
Vivek Kumar is using machine learning and computational science to examine frailty in mice to study the biology of aging. -
Research HighlightAugust 01, 2022Researching facilitators of cancer metastasis
Guangwen “Gary” Ren's new research shows that the structural cells in the lung (fibroblasts) drive myeloid cell dysfunction to create a more welcoming environment for metastatic cancer. -
Research HighlightJuly 07, 2022JAX team discovers mechanism for chemotherapy resistance
A team led by JAX's Edison Liu and Francesca Menghi used patient data, patient-derived xenograft (PDX) mouse models, and engineered cancer cell lines to investigate why people with BRCA mutations respond better and are less likely to develop platinum-based therapy resistance than patients with BRCA1 promoter methylation.
-
Featured ArticleSeptember 15, 2022JAX undertakes nationwide study to evaluate impact of genomic tumor boards on cancer care
The Jackson Laboratory announced today that it will take its cornerstone genomic tumor board program to oncologists across the nation as part of a SWOG Cancer Research Network study, in collaboration with Columbia University. -
Featured ArticleAugust 02, 2022Eric Wang is overcoming treatment resistance in leukemia
Eric Wang joins the JAX faculty to devise new strategies to overcome the development of drug resistance in cancer. -
Blog PostJuly 26, 2022Postbacc fellows at JAX preparing for MD PhDs
In 2017 JAX Genomic Education expanded to include recent college graduates in our new Postbaccalaureate Fellows Program. Let's meet six current 2022 Fellows. -
Featured ArticleJune 28, 2022JAX Genomic Medicine is increasing the precision of brain cancer diagnoses
The new technique of methylome profiling, now available from The Jackson Laboratory, provides more precise tumor classification for cancers of the central nervous system (CNS).